1
WGU D116 ADVANCED PHARMACOLOGY OA & PRE-
ASSESSMENT EXAM 2026/2027 | Actual Exam Complete
Questions with Verified Answers & Rationales | Already
Graded A+ | Pass Guaranteed
OBJECTIVE ASSESSMENT (OA) - 70 QUESTIONS - ALREADY GRADED A+
OA1: Pharmacokinetics & Pharmacodynamics - Advanced Principles (Q1-12)
Q1. A 68-year-old patient with cirrhosis is prescribed a drug that undergoes
extensive first-pass hepatic metabolism. The prescriber reduces the initial dose by
50%. Which pharmacokinetic principle explains this adjustment?
A. Decreased renal clearance requires dose reduction
B. Decreased hepatic blood flow and enzyme activity reduce first-pass metabolism,
increasing bioavailability
C. Increased plasma protein binding in liver disease reduces free drug concentration
D. Zero-order kinetics is more efficient in hepatic impairment
B. Decreased hepatic blood flow and enzyme activity reduce first-pass metabolism,
increasing bioavailability [CORRECT]
Rationale: Cirrhosis reduces hepatic blood flow and CYP450 enzyme activity,
diminishing first-pass metabolism and increasing systemic bioavailability; this
necessitates lower initial doses. Renal clearance is not the primary issue, protein
binding typically decreases (not increases) in cirrhosis, and zero-order kinetics is not
more efficient in hepatic impairment.
Correct Answer: B
Q2. A drug has a therapeutic index of 2.5. Which clinical implication is most accurate?
A. The drug is very safe with a wide margin between effective and toxic doses
B. The drug requires careful therapeutic drug monitoring because the toxic dose is
close to the effective dose
,2
C. The drug cannot cause toxicity at any dose
D. The drug exhibits zero-order kinetics at therapeutic doses
B. The drug requires careful therapeutic drug monitoring because the toxic dose is
close to the effective dose [CORRECT]
Rationale: A low therapeutic index (narrow margin between ED50 and TD50)
indicates a narrow safety margin requiring close monitoring; a high TI indicates
safety. All drugs can cause toxicity at excessive doses, and therapeutic index does not
determine kinetic order.
Correct Answer: B
Q3. A patient taking phenytoin for seizure control presents with toxic symptoms after
a small dose increase. Phenytoin metabolism follows zero-order kinetics at
therapeutic concentrations. Which statement explains this phenomenon?
A. A small dose increase produces a proportional increase in plasma concentration
B. A small dose increase produces a disproportionately large increase in plasma
concentration because enzyme saturation has occurred
C. The drug is metabolized faster as concentration increases
D. Zero-order kinetics means the drug is completely excreted unchanged
B. A small dose increase produces a disproportionately large increase in plasma
concentration because enzyme saturation has occurred [CORRECT]
Rationale: Zero-order kinetics occurs when metabolic enzymes are saturated, causing
plasma concentration to increase disproportionately to dose changes; first-order
kinetics shows proportional increases. Zero-order does not imply faster metabolism
or complete renal excretion.
Correct Answer: B
,3
Q4. A patient on warfarin begins taking ciprofloxacin and develops an elevated INR
with bleeding. Ciprofloxacin inhibits CYP1A2, CYP3A4, and affects vitamin K-
producing gut flora. Which pharmacokinetic interaction is primarily responsible?
A. Ciprofloxacin induces warfarin metabolism
B. Ciprofloxacin inhibits warfarin metabolism and reduces vitamin K synthesis,
increasing warfarin effect
C. Ciprofloxacin increases warfarin protein binding
D. Ciprofloxacin increases warfarin renal excretion
B. Ciprofloxacin inhibits warfarin metabolism and reduces vitamin K synthesis,
increasing warfarin effect [CORRECT]
Rationale: Ciprofloxacin inhibits CYP450 enzymes that metabolize warfarin and
suppresses gut flora that produce vitamin K, both mechanisms increasing warfarin
anticoagulant effect. Ciprofloxacin does not induce metabolism, increase protein
binding, or enhance renal excretion of warfarin.
Correct Answer: B
Q5. A drug with high lipid solubility and low molecular weight is administered orally.
Which factor most accurately predicts its ability to cross the blood-brain barrier?
A. High water solubility
B. High lipid solubility and low molecular weight facilitate CNS penetration
C. High plasma protein binding facilitates CNS penetration
D. Large molecular size facilitates CNS penetration
B. High lipid solubility and low molecular weight facilitate CNS penetration
[CORRECT]
Rationale: The blood-brain barrier is lipophilic; drugs with high lipid solubility and
low molecular weight cross readily. Water-soluble drugs cross poorly, protein-bound
drug cannot cross, and large molecules are excluded.
Correct Answer: B
, 4
Q6. A patient receives a loading dose of digoxin followed by a maintenance dose.
The loading dose is calculated based on the volume of distribution (Vd). Which
statement about Vd is correct?
A. Vd represents the actual physical volume of blood in the body
B. Vd is a theoretical volume relating the amount of drug in the body to plasma
concentration; high Vd indicates extensive tissue distribution
C. Vd is inversely proportional to drug clearance
D. Vd cannot be used to calculate loading doses
B. Vd is a theoretical volume relating the amount of drug in the body to plasma
concentration; high Vd indicates extensive tissue distribution [CORRECT]
Rationale: Vd is a proportionality constant, not a physical space; high Vd indicates
lipophilic drugs distributing extensively into tissues. Loading dose = Vd × target
concentration. Vd is not inversely proportional to clearance.
Correct Answer: B
Q7. A patient on carbamazepine begins taking St. John's wort and experiences
breakthrough seizures. St. John's wort induces CYP3A4. Which pharmacokinetic
principle explains the seizure recurrence?
A. St. John's wort inhibits carbamazepine metabolism
B. St. John's wort induces CYP3A4, increasing carbamazepine metabolism and
reducing plasma levels below therapeutic range
C. St. John's wort increases carbamazepine absorption
D. St. John's wort displaces carbamazepine from protein binding sites
B. St. John's wort induces CYP3A4, increasing carbamazepine metabolism and
reducing plasma levels below therapeutic range [CORRECT]
Rationale: CYP3A4 induction by St. John's wort accelerates carbamazepine
metabolism, lowering plasma concentrations and causing therapeutic failure. It does
not inhibit metabolism, increase absorption, or significantly alter protein binding.
Correct Answer: B
WGU D116 ADVANCED PHARMACOLOGY OA & PRE-
ASSESSMENT EXAM 2026/2027 | Actual Exam Complete
Questions with Verified Answers & Rationales | Already
Graded A+ | Pass Guaranteed
OBJECTIVE ASSESSMENT (OA) - 70 QUESTIONS - ALREADY GRADED A+
OA1: Pharmacokinetics & Pharmacodynamics - Advanced Principles (Q1-12)
Q1. A 68-year-old patient with cirrhosis is prescribed a drug that undergoes
extensive first-pass hepatic metabolism. The prescriber reduces the initial dose by
50%. Which pharmacokinetic principle explains this adjustment?
A. Decreased renal clearance requires dose reduction
B. Decreased hepatic blood flow and enzyme activity reduce first-pass metabolism,
increasing bioavailability
C. Increased plasma protein binding in liver disease reduces free drug concentration
D. Zero-order kinetics is more efficient in hepatic impairment
B. Decreased hepatic blood flow and enzyme activity reduce first-pass metabolism,
increasing bioavailability [CORRECT]
Rationale: Cirrhosis reduces hepatic blood flow and CYP450 enzyme activity,
diminishing first-pass metabolism and increasing systemic bioavailability; this
necessitates lower initial doses. Renal clearance is not the primary issue, protein
binding typically decreases (not increases) in cirrhosis, and zero-order kinetics is not
more efficient in hepatic impairment.
Correct Answer: B
Q2. A drug has a therapeutic index of 2.5. Which clinical implication is most accurate?
A. The drug is very safe with a wide margin between effective and toxic doses
B. The drug requires careful therapeutic drug monitoring because the toxic dose is
close to the effective dose
,2
C. The drug cannot cause toxicity at any dose
D. The drug exhibits zero-order kinetics at therapeutic doses
B. The drug requires careful therapeutic drug monitoring because the toxic dose is
close to the effective dose [CORRECT]
Rationale: A low therapeutic index (narrow margin between ED50 and TD50)
indicates a narrow safety margin requiring close monitoring; a high TI indicates
safety. All drugs can cause toxicity at excessive doses, and therapeutic index does not
determine kinetic order.
Correct Answer: B
Q3. A patient taking phenytoin for seizure control presents with toxic symptoms after
a small dose increase. Phenytoin metabolism follows zero-order kinetics at
therapeutic concentrations. Which statement explains this phenomenon?
A. A small dose increase produces a proportional increase in plasma concentration
B. A small dose increase produces a disproportionately large increase in plasma
concentration because enzyme saturation has occurred
C. The drug is metabolized faster as concentration increases
D. Zero-order kinetics means the drug is completely excreted unchanged
B. A small dose increase produces a disproportionately large increase in plasma
concentration because enzyme saturation has occurred [CORRECT]
Rationale: Zero-order kinetics occurs when metabolic enzymes are saturated, causing
plasma concentration to increase disproportionately to dose changes; first-order
kinetics shows proportional increases. Zero-order does not imply faster metabolism
or complete renal excretion.
Correct Answer: B
,3
Q4. A patient on warfarin begins taking ciprofloxacin and develops an elevated INR
with bleeding. Ciprofloxacin inhibits CYP1A2, CYP3A4, and affects vitamin K-
producing gut flora. Which pharmacokinetic interaction is primarily responsible?
A. Ciprofloxacin induces warfarin metabolism
B. Ciprofloxacin inhibits warfarin metabolism and reduces vitamin K synthesis,
increasing warfarin effect
C. Ciprofloxacin increases warfarin protein binding
D. Ciprofloxacin increases warfarin renal excretion
B. Ciprofloxacin inhibits warfarin metabolism and reduces vitamin K synthesis,
increasing warfarin effect [CORRECT]
Rationale: Ciprofloxacin inhibits CYP450 enzymes that metabolize warfarin and
suppresses gut flora that produce vitamin K, both mechanisms increasing warfarin
anticoagulant effect. Ciprofloxacin does not induce metabolism, increase protein
binding, or enhance renal excretion of warfarin.
Correct Answer: B
Q5. A drug with high lipid solubility and low molecular weight is administered orally.
Which factor most accurately predicts its ability to cross the blood-brain barrier?
A. High water solubility
B. High lipid solubility and low molecular weight facilitate CNS penetration
C. High plasma protein binding facilitates CNS penetration
D. Large molecular size facilitates CNS penetration
B. High lipid solubility and low molecular weight facilitate CNS penetration
[CORRECT]
Rationale: The blood-brain barrier is lipophilic; drugs with high lipid solubility and
low molecular weight cross readily. Water-soluble drugs cross poorly, protein-bound
drug cannot cross, and large molecules are excluded.
Correct Answer: B
, 4
Q6. A patient receives a loading dose of digoxin followed by a maintenance dose.
The loading dose is calculated based on the volume of distribution (Vd). Which
statement about Vd is correct?
A. Vd represents the actual physical volume of blood in the body
B. Vd is a theoretical volume relating the amount of drug in the body to plasma
concentration; high Vd indicates extensive tissue distribution
C. Vd is inversely proportional to drug clearance
D. Vd cannot be used to calculate loading doses
B. Vd is a theoretical volume relating the amount of drug in the body to plasma
concentration; high Vd indicates extensive tissue distribution [CORRECT]
Rationale: Vd is a proportionality constant, not a physical space; high Vd indicates
lipophilic drugs distributing extensively into tissues. Loading dose = Vd × target
concentration. Vd is not inversely proportional to clearance.
Correct Answer: B
Q7. A patient on carbamazepine begins taking St. John's wort and experiences
breakthrough seizures. St. John's wort induces CYP3A4. Which pharmacokinetic
principle explains the seizure recurrence?
A. St. John's wort inhibits carbamazepine metabolism
B. St. John's wort induces CYP3A4, increasing carbamazepine metabolism and
reducing plasma levels below therapeutic range
C. St. John's wort increases carbamazepine absorption
D. St. John's wort displaces carbamazepine from protein binding sites
B. St. John's wort induces CYP3A4, increasing carbamazepine metabolism and
reducing plasma levels below therapeutic range [CORRECT]
Rationale: CYP3A4 induction by St. John's wort accelerates carbamazepine
metabolism, lowering plasma concentrations and causing therapeutic failure. It does
not inhibit metabolism, increase absorption, or significantly alter protein binding.
Correct Answer: B
